The Program Leaders for the Markey Cancer Center (MCC) provide cohesive leadership for promoting the research activities within and among the program areas. They assure continued interchange, program planning and evaluation, and educational exchange within their program. The Program Leaders identify areas of need within their research program and work with leadership of the cancer center to establish priorities and pursue recruitment in their respective areas. They are involved in identifying the shared resource needs of their program members and encourage collaborations between programs by communicating with leaders of other programs on possible areas of interactions and collaborations. They inform the appropriate Associate Director and the MCC Director on program activities and serve on the MCC's Scientific Advisory Panel and the Program and Shared Resource Leaders Committee. The four research programs of the MCC) are: Program 1: Cancer Cell Biology and Signaling Program 2: Cancer Prevention and Control Program 3: Drug Discovery, Delivery and Translational Therapeutics Program 4: Redox Injury and Repair

Public Health Relevance

The four Markey Cancer Center research programs provide an exchange of scientific knowledge with their program members and with members of the other research programs by collaborating on innovative research studies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA177558-02
Application #
8740635
Study Section
Subcommittee B - Comprehensiveness (NCI)
Project Start
Project End
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
2
Fiscal Year
2014
Total Cost
Indirect Cost
Name
University of Kentucky
Department
Type
DUNS #
City
Lexington
State
KY
Country
United States
Zip Code
40506
Wei, Xiaowei; Xu, Yong; Xu, Fang Fang et al. (2017) RelB Expression Determines the Differential Effects of Ascorbic Acid in Normal and Cancer Cells. Cancer Res 77:1345-1356
Cui, Jiajun; Xu, Wenhua; Chen, Jian et al. (2017) M2 polarization of macrophages facilitates arsenic-induced cell transformation of lung epithelial cells. Oncotarget 8:21398-21409
Wu, Yadi; Wang, Yu; Lin, Yiwei et al. (2017) Dub3 inhibition suppresses breast cancer invasion and metastasis by promoting Snail1 degradation. Nat Commun 8:14228
Wise, James T F; Wang, Lei; Zhang, Zhuo et al. (2017) The 9th Conference on Metal Toxicity and Carcinogenesis: The conference overview. Toxicol Appl Pharmacol 331:1-5
Carpenter, Brittany L; Liu, Jinpeng; Qi, Lei et al. (2017) Integrin ?6?4 Upregulates Amphiregulin and Epiregulin through Base Excision Repair-Mediated DNA Demethylation and Promotes Genome-wide DNA Hypomethylation. Sci Rep 7:6174
Jarrett, Stuart G; D'Orazio, John A (2017) Hormonal Regulation of the Repair of UV Photoproducts in Melanocytes by the Melanocortin Signaling Axis. Photochem Photobiol 93:245-258
Li, Liqing; Li, Xiang; Qi, Lei et al. (2017) The role of talin2 in breast cancer tumorigenesis and metastasis. Oncotarget 8:106876-106887
Kenlan, Dasha E; Rychahou, Piotr; Sviripa, Vitaliy M et al. (2017) Fluorinated N,N'-Diarylureas As Novel Therapeutic Agents Against Cancer Stem Cells. Mol Cancer Ther 16:831-837
Son, Young-Ok; Pratheeshkumar, Poyil; Divya, Sasidharan Padmaja et al. (2017) Nuclear factor erythroid 2-related factor 2 enhances carcinogenesis by suppressing apoptosis and promoting autophagy in nickel-transformed cells. J Biol Chem 292:8315-8330
Arnold, Susanne M; Chansky, Kari; Leggas, Markos et al. (2017) Phase 1b trial of proteasome inhibitor carfilzomib with irinotecan in lung cancer and other irinotecan-sensitive malignancies that have progressed on prior therapy (Onyx IST reference number: CAR-IST-553). Invest New Drugs 35:608-615

Showing the most recent 10 out of 281 publications